Dermatology
| Hidradenitis Suppurativa
Dermatology
Hidradenitis Suppurativa
Efficacy and safety of izokibep, a novel IL-17A inhibitor, in moderate-to-severe hidradenitis suppurativa: Week 12 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study
book_2
Source:
EADV 2024 - Oral session
calendar_today
Published on Medfyle:
October 2024
import_contacts
4
min
In this medfyle
This late-breaking abstract at EADV 2024 showcases the efficacy and safety of izokibep – a novel IL-17A inhibitor – in moderate-to-severe hidradenitis suppurativa.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Efficacy and safety of izokibep, a novel IL-17A inhibitor, in moderate-to-severe hidradenitis suppurativa: Week 12 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study. Papp KA, et al. Presented at EADV 2024; Abstract #7995.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
